MannKind Corporation (MNKD)

3.0900 +0.1400 (+4.75%) As of 11:11AM EST. Market open.

MannKind Corporation

30930 Russell Ranch Road
Suite 300
Westlake Village, CA 91362
United States
818 661 5000
http://www.mannkindcorp.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 232

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Michael E. Castagna	CEO & Director	844.2k	N/A	1977
Mr. Steven B. Binder	Chief Financial Officer	630.4k	N/A	1963
Dr. David B. Thomson	Corp. VP, Gen. Counsel & Sec.	675.97k	N/A	1967
Mr. James Patrick McCauley Jr., J.D., M.B.A.	Chief Commercial Officer	614.06k	N/A	1966
Mr. Joseph Kocinsky	Chief Technology Officer	N/A	N/A	1964
Ms. Rosabel Realica Alinaya	VP of Investor Relations & Treasury	N/A	N/A	1961
Dr. Stuart A. Tross	Chief People & Workplace Officer	N/A	N/A	1967
Mr. John F. Bedard	Sr. VP of Worldwide Regulatory Affairs	N/A	N/A	1950
Mr. Alejandro Galindo M.B.A., M.S.	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension. MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, California.

Corporate Governance

MannKind Corporation’s ISS Governance QualityScore as of November 1, 2019 is 8. The pillar scores are Audit: 5; Board: 7; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.